UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C.  20549

                                  FORM 10-Q
X    QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

                   For the quarterly period ended September 30, 2006

                                     OR

     TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

For the transition period from                      to

                   Commission File Number           000-20175

                                 NYER MEDICAL GROUP, INC.
                  (Exact name of registrant as specified in its charter)

                         Florida                               01-0469607
              (State or other jurisdiction of               (I.R.S. Employer
              incorporation or organization)                Identification No.)

                 1292 Hammond Street, Bangor, Maine               04401
              (Address of principal executive offices)          (Zip Code)

                                       (207) 942-5273
                   (Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.      Yes  [X]  No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer.  See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]   Accelerated filer [ ]   Non-accelerated filer [X]

Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).         Yes       No  X

As of November 13, 2006 there were 3,978,199 shares of common stock
outstanding, par value $.0001 per share.



                                1 of 24

 FORM 10-Q    NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006

                                      INDEX


                                                                    Page No.

                     PART I - FINANCIAL INFORMATION

  Item 1.  Financial Statements:

           Consolidated Balance Sheets, September 30, 2006
             and June 30, 2006                                            4
           Consolidated Statements of Operations, Three Months
             Ended September 30, 2006 and September 30, 2005              6
           Consolidated Statements of Cash Flows, Three Months
             Ended September 30, 2006 and September 30, 2005              7
           Selected Notes to Consolidated Financial Statements            9

  Item 2.  Management's Discussion and Analysis of Financial
             Condition and Results of Operations                         15

  Item 3.  Quantitative and Qualitative Disclosures About
             Market Risk                                                 18

  Item 4.  Controls and Procedures                                       19


                          PART II - OTHER INFORMATION

  Item 1.  Legal Proceedings                                             19

  Item 1A. Risk Factors                                                  20

  Item 2.  Unregistered Sales of Equity Securities and Use of
           Proceeds                                                      20

  Item 3.  Defaults Upon Senior Securities                               21

  Item 4.  Submissions of Matters to a Vote of Security Holders          21

  Item 5.  Other Information                                             21

  Item 6.  Exhibits                                                      21

            Signatures                                                   22









                                         2

FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006

     Certain statements contained in this report are forward-looking in nature.
These statements are generally identified by the inclusion of phrases such as
"we expect", "we anticipate", "we believe", "we estimate" and other phrases of
similar meaning.  Whether such statements ultimately prove to be accurate
depends upon a variety of factors that may affect our business and operations.
Many of these factors are described in our most recent Annual Report on Form
10-K as filed with Securities and Exchange Commission.

     We make available on our website free of charge our annual report on
Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and
amendments to such reports as soon as practicable after we electronically file
such reports with the SEC.  Our website address is www.nyermedicalgroup.com.
The information contained in our website is not incorporated by reference in
this Report.







































                                          3

  FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006

                         PART I - Financial Information

Item 1.  Financial Statements:

                        NYER MEDICAL GROUP, INC AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS

                                     ASSETS


                                           September 30,       June 30,
                                              2006              2006
                                              ----              ----
                                           (Unaudited)

Current assets:
  Cash                                     $ 1,191,372       $   814,119
  Accounts receivable, less allowance
   for doubtful accounts of $101,000
   at September 30, 2006 and $143,000
   at June 30, 2006                          4,830,902         5,244,779
  Inventories                                6,189,623         6,153,597
  Prepaid expenses and other current
   assets                                      237,415           256,877
  Refundable income taxes                       24,720            42,720
  Current portion of deferred tax
   assets                                      216,000           238,000
                                           -----------       -----------
      Total current assets                  12,690,032        12,750,092
                                           -----------       -----------
Property, plant and equipment, net
 of accumulated depreciation                 1,430,522         1,490,999
                                           -----------       -----------
Goodwill                                       104,463           104,463
Other intangible assets                        660,531           690,635
Long-term portion of deferred
 tax asset                                     372,100           362,000
Other assets                                    51,321            51,321
                                           -----------       -----------
                                             1,188,415         1,208,419
                                           -----------       -----------

      Total assets                         $15,308,969       $15,449,510
                                           ===========       ===========








     See accompanying notes to consolidated financial statements.
                                          4

FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                       NYER MEDICAL GROUP, INC AND SUBSIDIARIES
                              CONSOLIDATED BALANCE SHEETS

                           LIABILITIES AND SHAREHOLDERS' EQUITY

                                           September 30,       June 30,
                                              2006              2006
                                              ----              ----
                                           (Unaudited)
Current liabilities:

  Current portion of long-term debt        $   190,299       $   190,728
  Accounts payable                           3,811,046         3,694,954
  Accrued payroll and related taxes            563,637           592,558
  Accrued expenses and other liabilities       197,514           268,936
  Income taxes payable                               -           135,000
  Liabilities to be disposed of from
   discontinued operations                     298,628           298,628
                                           -----------        ----------
            Total current liabilities        5,061,124         5,180,804
                                           -----------        ----------

Long-term debt, net of current
  portion                                      244,520           291,739
                                            ----------        ----------
Minority interest                            1,669,188         1,648,029
                                            ----------        ----------

Shareholders' equity:
  Preferred stock                                    1                 1
  Common stock                                     398               398
  Additional paid-in capital                18,057,523        18,047,110
  Accumulated deficit                       (9,723,785)       (9,718,571)
                                           -----------       -----------
            Total shareholders'
             equity                          8,334,137         8,328,938
                                           -----------       -----------
            Total liabilities and
             shareholders' equity          $15,308,969       $15,449,510
                                           ===========       ===========












     See accompanying notes to consolidated financial statements.


                                          5
FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                      NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
                  CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

                                              For the three months ended
                                           September 30,   September 30,
                                               2006            2005
                                               ----            ----
Revenues:
  Sales                                   $16,383,306      $14,807,962
  Dispensing fees                             498,345          368,487
                                          -----------      -----------
Total revenues                             16,881,651       15,176,449

Cost of goods sold:                        12,988,657       11,666,429
                                          -----------      -----------
  Gross profit                              3,892,994        3,510,020

Operating expenses:

  Selling, general and administrative
    expenses                                3,726,509        3,188,085
  Depreciation and amortization               137,183          117,610
                                          -----------      -----------
      Total operating expenses              3,863,692        3,305,695
                                          -----------      -----------
  Operating income                             29,302          204,325
                                          -----------      -----------
Other income (expense):
  Interest expense                             (6,737)          (2,510)
  Interest income                               5,179            9,547
  Other                                        18,101             (766)
                                          -----------      -----------
       Total other income                      16,543            6,271
                                          -----------      -----------
Income before income taxes and
  minority interest                            45,845          210,596

Provision for income taxes                    (29,900)         (91,400)

Minority interest expense, net
  of income taxes expense                     (21,159)         (32,099)
                                          -----------      -----------
Net (loss) income                         $    (5,214)     $    87,097
                                          ===========      ===========
Basic and diluted income per share:       $         -      $       .02
                                          ===========      ===========
Weighted average common
   shares outstanding, basic                3,978,199        3,978,199
                                            =========        =========
Weighted average common
   shares outstanding, diluted              3,978,199        4,311,631
                                            =========        =========

             The accompanying notes are an integral part of the consolidated
                            financial statements.
                                          6
FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                      NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
                   CONSOLIDATED STATEMENTS OF CASH FLOWS, (unaudited)

                                            For the three months ended
                                           September 30,   September 30,
                                               2006            2005
                                               ----            ----
                                                              Revised
Cash flows from operating activities:

  Net (loss) income                        $     (5,214)    $     87,097

  Adjustments to reconcile net (loss)
   income to net cash provided by (used
   in) operating activities:
  Depreciation                                  107,079           96,643
  Amortization                                   30,104           20,967
  Stock-based compensation expense               10,413           11,938
  Deferred income tax                            11,900                -
  Minority interest                              21,159           32,099
  Changes in working capital                    296,062         (902,266)
                                           ------------     ------------
 Net cash flows provided by (used in)
  operating activities from continuing
  operations                                    471,503         (653,522)
                                           ------------     ------------
Cash flows from investing activities:

 Purchase of property, plant and
   equipment, net                               (46,602)         (80,749)
                                           ------------     ------------
 Net cash flows used in investing
   activities                                   (46,602)         (80,749)
                                           ------------     ------------
Cash flows from financing activities:

 Payments on long-term debt                     (47,648)         (42,512)
                                           ------------     ------------
Net cash flows used in financing
  activities                                    (47,648)         (42,512)
                                           ------------     ------------
Net cash flows provided by
  discontinued activities                             -            2,062
                                           ------------     ------------
Net increase (decrease) in cash                 377,253         (774,721)
Cash at beginning of period                     814,119        1,993,905
                                           ------------     ------------
Cash at end of period                      $  1,191,372     $  1,219,184
                                           ============     ============


            The accompanying notes are an integral part of the consolidated
                                  financial statements.
                                          continued
                                          7

  FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                          NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
               CONSOLIDATED STATEMENTS OF CASH FLOWS, (unaudited), continued

                                            For the three months ended
                                           September 30,   September 30,
                                               2006            2005
                                               ----            ----
 Changes in working capital:

  Accounts receivable                      $    413,877     $    123,835
  Inventories                                   (36,026)         (46,235)
  Prepaid expenses and other current
   assets                                        19,462           16,093
  Refundable income taxes                        18,000                -
  Accounts payable                              116,092         (733,925)
  Accrued payroll and related taxes             (28,921)         (72,090)
  Accrued expenses and other liabilities        (71,422)        (138,737)
  Income tax payable                           (135,000)         (51,207)
                                           ------------     ------------
      Net change                           $    296,062     $   (902,266)
                                           ============     ============

  Supplemental disclosures of cash flow information:

                                            For the three months ended
                                           September 30,   September 30,
                                               2006            2005
                                               ----            ----
Cash paid during the period for:

Interest                                   $      6,903     $      2,889
                                           ============     ============
Income taxes                               $    135,000     $    182,500
                                           ============     ============




















                                          8

FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                        NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
             SELECTED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

1. Accounting Policies:
   -------------------
Basis of Presentation

     The consolidated financial statements included herein have been prepared
by the Company, without audit, in accordance with accounting principals
generally accepted in the United States of America and pursuant to the rules
and regulations of the Securities and Exchange Commission.  Certain information
and footnote disclosures normally included in financial statements prepared in
accordance with accounting principals generally accepted in the United States
of America have been condensed or omitted pursuant to such rules and
regulations, although the Company believes that the disclosures are adequate
to make the information presented not to be misleading.  In the opinion of
management, the amounts shown reflect all adjustments necessary to present
fairly the financial position and results of operations for the periods
presented.  All such adjustments are of a normal recurring nature.

     It is suggested that the financial statements be read in conjunction
with the financial statements and notes thereto included in the Company's Form
10-K/Amendment No. 1 for the year ended June 30, 2006.

     Reclassifications

     Prior year information is reclassified whenever necessary to conform to
current year's presentation.

     Revisions

     The Company revised its consolidated statements of cash flows for the
three months ended September 30, 2005 to separately disclose the cash flows
attributable to discontinued operations below net cash flows (used in) provided
by financing activities.  The Company previously reported these amounts in net
cash flows provided by operating activities in its report on Form 10-Q for the
three months ended September 30, 2005.

2.  Stock Based Compensation:
    ------------------------
     The Company adopted Statement of Financial Accounting Standards (SFAS)
No. 123R, "Share-Based Payment," effective July 1, 2005, which requires
companies to record compensation expense for stock options issued to employees
or non-employee directors at the fair value of the options.

     The Company adopted SFAS No. 123R using the "modified prospective
application" and, therefore, financial statements from periods ending prior to
July 1, 2005 have not been restated.  As a result of adopting SFAS No. 123R, the
Company recorded stock based compensation expenses of $10,413 and $11,938 for
the three months ended September 30, 2006 and 2005, respectively.

3.  Restricted Assets and Uncertainties
    -----------------------------------
     The Pharmacy acquisition agreements, described below, include provisions
whereby the pharmacies pay a specific management fee to its parent.  In
addition, such agreements provide that the Shareholders (as defined below)
manage day-to-day operations of the pharmacies, which has included cash
management.
                                          9

  FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                       NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
          SELECTED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

3.  Restricted Assets and Uncertainties, continued
    -----------------------------------
     In August of 1996, the Company and the shareholders of D.A.W. entered into
a stock exchange agreement and plan of reorganization whereby the Company
acquired by exchange with the sellers 80% of the issued and outstanding stock
of D.A.W.  The Board of Directors of D.A.W. is comprised of five members, two
designated by the minority shareholders (the "Shareholders")and two designated
by the Company and a fifth director not affiliated with the Shareholders or the
Company.  The fifth seat on the board is vacant.

     As part of an associated shareholders' agreement, the Company and
the Shareholders will not vote any of their shares in favor of, or consent to
any merger of D.A.W. with another entity or any sale of all or substantially
all of the assets of D.A.W. unless 80% of the D.A.W.'s Board of Directors vote
in favor of the transaction.

     Four of the five Shareholders (and the husband of another Shareholder)
had employment agreements which expired in August 2006.  When the agreements
expired, the Shareholders had the right to require the Company to purchase all
or any portion of their shares of D.A.W.

     In August 2006, the Company and the employees agreed to enter into oral
employment agreements on the same terms as the expired agreements.  However,
the employees and the Company are presently negotiating new employment
agreements and/or a buy out agreeable to all parties.  There is no assurance
that the Company will be able to successfully negotiate employment agreements
and/or raise the capital necessary to buy out the Shareholders.

     There is no assurance that management's business plan will be successful.
If the capital cannot be raised before the required date for the Put Shares
to be purchased by the Company, then the Shareholders may enforce their rights
to have the Put Shares purchased.  At this time, the Company does not have
an alternative plan to satisfy the Shareholders, and the Shareholders may than
seek to enforce their rights in a manner which would be materially adverse
to the Company and its shareholders.  The financial statements do not include
any adjustments that might result from the outcome of these uncertainties.

     In August 2006, the Company entered into an Agreement with the Shareholders
which is stated/accomplished the following:

     The Company acknowledges that 100% of the shares of the subsidiaries of
the Company (the "Subsidiaries") held by each Shareholder (the "Put Shares")
have been offered to the Company for purchase.

     The Shareholders agree to refrain from requiring the Company to
immediately pay the fair market value of the Put Shares until the earlier of
(i) the closing of the transaction(s) among the Company, the Shareholders and
the Subsidiaries with respect to the potential purchase by the Company of all
of the shares held by the Shareholders in the Subsidiaries (the "Purchase"),
which may be accomplished by payment in full of immediately available funds,
and (ii) July 15, 2007.
                                          10

FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                      NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
             SELECTED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

3.  Restricted Assets and Uncertainties, continued
    -----------------------------------
     The Company agrees to pay $16,665 per month in total to certain
Shareholders of from the first business day of August, 2006 until the earlier
of (i) the closing of the Purchase, and (ii) December 15, 2006; and $33,335
per month from and after December 16, 2006 until the closing of the Purchase.

     D.A.W. agrees to advance to the Company the amounts necessary to make the
monthly payments (with interest at the applicable federal rate) upon the
earlier of (i) the closing of the Purchase, and (ii) July 15, 2007.

     The Company pledged 2.5 percent of its holdings in D.A.W. as collateral
for the monies advanced to the Company by D.A.W. to make the monthly payments
noted above.

     The parties to the Agreement agreed that the fair market value of all of
the shares of the Subsidiaries held by the Shareholders is $4 million.

     Should an agreement not be reached and/or capital not be raised, the
Company will be faced with a number of uncertainties:

     If an agreement has not been finalized by July 15, 2007, the Shareholders
could seek employment elsewhere.  This would, in the short run, leave no
management team for the pharmacies and cause the Company to have to assemble an
entire new management team.

     Two of the store leases are expiring in fiscal year 2007.  There is no
assurance that D.A.W. will be able to renew the other leases at terms
acceptable to management.

     The store lease of the largest and most profitable location, which is
owned by the mother of D.A.W.'s president, was renewed in October of 2006 for
five years with an option for an additional five years.  Should the agreement
mentioned above not be negotiated successfully, the owner has the option to
cancel the lease.

4.  Other intangible:
    ----------------
    The following is a summary of other intangible assets:


    September 30, 2006   Amortization               Accumulated
                         Period (years)   Cost      Amortization      Net
                         -------------    ----      ------------      ---
    Prescription lists        9.5     $  751,500      $171,419      $580,081
    Non-compete agreements    1.5        340,000       259,550        80,450
                                      ----------      --------      --------
Totals                                $1,091,500      $430,969      $660,531
                                      ==========      ========      ========
    June 30, 2006        Amortization               Accumulated
                         Period (years)   Cost      Amortization      Net
                         -------------    ----      ------------      ---

    Prescription lists        9.8     $  751,500      $156,132      $595,368
    Non-compete agreements    1.8        340,000       244,733        95,267
                                      ----------      --------      --------
        Totals                        $1,091,500      $400,865      $690,635
                                      ==========      ========      ========
    Amortization expense of intangible assets was $30,104 and $29,302 for the
three months ended September 30, 2006 and 2005.

                                          11

FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                      NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
             SELECTED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

4.  Other intangible: continued,
    -----------------

     Based on the balance of intangible assets at September 30, 2006, the
annual amortization expense for each of the succeeding five years is estimated
to be as follows:

                      Year              Amortization amount
                      ----              -------------------
                      2007                 $ 89,900
                      2008                   97,000
                      2009                   61,000
                      2010                   61,000
                      2011                   61,000
                      Thereafter            290,631
                                           --------
                        Total              $660,531
                                           ========

5.  Discontinued operations:
    -----------------------
     The following table shows liabilities of discontinued operations (fire
and police segment) at September 30:

                                             2006          2005
                                             ----          ----
   Accounts payable                        $251,957       $251,857
   Accrued expenses and other
     liabilities                             46,671         47,292
                                           --------       --------
       Total liabilities                   $298,628       $299,149
                                           ========       ========
6.  Earnings per share:
    ------------------
     The following data show the amounts used in computing earnings per share
and the weighted average number of share of diluted potential common stock
at September 30:


                                                2006            2005
                                                ----            ----
Weighted average number of common
 shares used in basic EPS                    3,978,199       3,978,199
Stock options                                        -         333,432
Weighted average number of common            ---------       ---------
 shares used in diluted EPS                  3,978,199       4,311,631
                                             =========       =========
     In 2006, the options were anti-dilutive due to a loss for the period ended
September 30, 2006.  Certain options were not included in the computation of
diluted earnings per share in 2005 because the exercise prices of these options
were greater than the average market price of the common shares and the options
were therefore anti-dilutive.

7.  Contingencies:
    -------------
     Legal proceedings
     -----------------
    The Company is subject to various legal proceedings and threatened legal
proceedings from time to time as part of its business.
                                          12

FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                     NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
             SELECTED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

7.  Contingencies: continued,
    -------------
     Legal proceedings, continued,
     -----------------
     In April, 2006, a former employee of the pharmacy segment filed a civil
action against the pharmacy segment in the United States District Court for the
District of Massachusetts, alleging that the pharmacy segment improperly
classified its pharmacists as exempt from the overtime requirements of the Fair
Labor Standards Act and failed to make overtime payments to them under the FLSA
and an analogous state law.  The former employee sought payment of overtime from
April 2003 through April 2006, penalties and attorney's fees.  The action
originally was brought as a class action.  On October 20, 2006, the pharmacy
segment and the former employee settled this matter with the pharmacy segment
agreeing to pay the former employee the total amount of $15,000.

     In April, 2006, the former employee also filed a Charge of Discrimination
with the Massachusetts Commission Against Discrimination ("MCAD") against the
pharmacy segment and an officer of the pharmacy segment, alleging that the
former employee was subjected to discrimination and sexual harassment that
resulted in her constructive termination.  The pharmacy segment filed a
position statement with the MCAD on June 26, 2006 denying the allegations and
requesting that the MCAD issue a lack of probable cause finding and dismiss the
charge.  On August 16, 2006, the former employee withdrew the Charge of
Discrimination from the MCAD, and, the next day, filed a civil action in the
Middlesex Division of the Superior Court Department of the Massachusetts Trial
Court raising allegations identical to those in the MCAD charge.  The complaint
seeks back pay, emotional distress and punitive damages and attorneys' fees in
unspecified amounts.  The pharmacy segment filed its answer on September 14,
2006, and discovery has commenced.  The likelihood of success of this
litigation matter has not yet been determined.  Accordingly the Company cannot
determine at this time if the claim is material.

     Anton Investments, Inc. and Conway Associates, Inc. have litigation
threatened against them with respect to amounts owed.  The entities have not
yet determined the likelihood of success of these potential litigation matters.
The Company does not believe that the dollar amount of possible damages
regarding these litigation matters threatened would be material.  Even if these
matters were all decided in a manner adverse to the Company, there would not
likely be a material adverse affect on the Company and its subsidiaries.  It
should be noted that this paragraph describes litigation which has been
threatened but for which no complaint has been filed against the Company or any
of its subsidiaries.  It is possible that no suit will be filed with respect to
these matters.

     Any potential litigation, regardless of its merits, could result in costs
to the Company and divert management's attention from operations.

                                          13

FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                     NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
             SELECTED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

8.  Business Segments:
    -----------------
     The Company had two business segments for three months ended September
30: (1) pharmacies and (2) wholesale and retail sales of surgical, medical
equipment and supplies ("medical").  Business segments are determined by the
management approach which analyses segments based on products or services
offered for sale.  Corporate assets include assets of discontinued
operations.
                                        2006          2005
                                        ----          ----
     Net revenues

          Pharmacies                 $15,464,410   $13,272,385
          Medical                      1,417,241     1,904,064
                                     -----------   -----------
                                     $16,881,651   $15,176,449
                                     ===========   ===========
     Operating income

          Pharmacies                 $   196,520   $   301,335
          Medical                         (4,941)          656
          Corporate                     (162,277)      (97,666)
                                     -----------   -----------
                                     $    29,302   $   204,325
                                     ===========   ===========
     Identifiable assets

          Pharmacies                 $13,115,392   $11,467,398
          Medical                      1,491,338     1,589,188
          Corporate                      702,239       379,566
                                     -----------   -----------
                                     $15,308,969   $13,436,152
                                     ===========   ===========


     Capital expenditures

          Pharmacies                 $    31,309   $    80,749
          Medical                         15,293             -
                                     -----------   -----------
                                     $    46,602   $    80,749
                                     ===========   ===========
     Depreciation and Amortization

          Pharmacies                 $   123,304   $   100,169
          Medical                         13,879        17,441
                                     -----------   -----------
                                     $   137,183   $   117,610
                                     ===========   ===========
     Interest expense

          Pharmacies                 $     6,638   $     2,134
          Medical                             99           376
                                     -----------   -----------
                                     $     6,737   $     2,510
                                     ===========   ===========
     Income taxes

          Pharmacies                 $    75,300   $   107,000
          Medical                           (400)        6,500
          Corporate                      (45,000)      (22,100)
                                     -----------   -----------
                                     $    29,900   $    91,400
                                     ===========   ===========
                                          14
FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                       NYER MEDICAL GROUP, INC. AND SUBSIDIARIES

Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
            RESULTS OF OPERATIONS

Results of Operations:

     The following discussion provides information with respect to our results
of operations, liquidity, and capital resources on a comparative basis for the
three months ended September 30, 2006 and 2005.

Net Revenues.  Total revenues for the three months ended September 30, 2006
increased by $1,705,202 or 11.2% to $16,881,651 from $15,176,449 for the three
months ended September 30, 2005.

     The following table shows revenues by business segment for the three
months ended September 30:

Business Segment                      2006           2005    % Increase
                                      ----           ----     (decrease)
                                                             ----------
Pharmacies                       $15,464,410     $13,272,385     16.5
Medical                            1,417,241       1,904,064    (25.6)
                                 -----------     -----------
                                 $16,881,651     $15,176,449     11.2
                                 ===========     ===========
     The pharmacies segment's revenues increased $2,192,025 to $15,464,410 or
16.5% for the three months ended September 30, 2006 as compared to $13,272,385
for the three months ended September 30, 2005.  The pharmacies' revenues
(excluding dispensing fees) increased $2,062,167 to $14,966,065 or 16.2% for
the three months ended September 30, 2006 as compared to $12,903,898 for the
three months ended September 30, 2005. The pharmacy segment acquired a new
location in April 2006, which accounts for approximately $1,100,000 or 8.3% of
the increase for the three months ended September 30, 2006.  The remainder of
the increase is due to growth of the federal Medicare Part D drug benefit and
the aging of the American population resulting in increased drug utilization.
Dispensing fees revenue increased $129,858 to $498,435 or 35.2% for the three
months ended September 30, 2006 as compared to $368,487 for the three months
ended September 30, 2005.  The pharmacies executed two new contracts (December
2005 and June 2006) with federally qualified health centers (FQHC), which
accounted for approximately $30,100 of the increase.  The remainder of the
increase was due to increased volume in the existing locations.  Dispensing
fees revenue is recognized from contracts with FQHC.  The pharmacies manage
three pharmacies owned by federally qualified health centers.  The pharmacies
also have contracts to provide pharmacy services to patients of three other
federally qualified health centers.  The pharmacies maintain a segregated
inventory owned by the health centers for the purpose of dispensing
prescriptions to health center patients.  They recognize dispensing fees when a
prescription is dispensed from the segregated inventory owned by the FQHC.

     The medical segment's sales decreased $486,823 to $1,417,241 or 25.6% for
the three months ended September 30, 2006 as compared to $1,904,064 for the
three months ended September 30, 2005.  Internet sales decreased by
approximately $355,000 due to lower equipment sales as the Company has
increased prices for equipment eliminating unprofitable sales.  Also, Internet
sales have decreased due to switching to a new website platform which does not
contain all of the Company's products.  The remaining decrease of approximately
$131,800 was due to the medical segment continuing to be pressured by regional
and national buying groups able to command larger discounts from manufacturers
whom are able to offer on-line purchasing, inventory controls as well as larger
competitors who offer lower prices.
                                          15

 FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                       NYER MEDICAL GROUP, INC. AND SUBSIDIARIES

Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
         RESULTS OF OPERATIONS, continued,

Results of Operations: continued,

Gross Profit Margins.  The overall gross profit margins were 23.1% for the
three months ended September 30, 2006 and 2005.

     The following is a table of gross profit margin percentages by business
segment for the three months ended September 30:

Business Segment                      2006            2005      % Increase
                                      ----            ----      ----------
Pharmacies                            22.4            22.4          -
Medical                               30.5            28.3         7.1

     The pharmacies segment's gross profit margins remained the same at 22.4%
for the three months ended September 30, 2006 and 2005.

     The medical segment's gross profit margins increased 7.1% to 30.5% for the
three months ended September 30, 2006 as compared to 28.3% for the three months
ended September 30, 2005.  The increase was the result of the implementation of
a higher pricing structure on Internet sales.

Selling, General and Administrative Expenses.  Consolidated selling, general
and administrative expenses ("S,G&A") increased 16.9% for the three months
ended September 30, 2006 to $3,726,509 as compared to $3,188,085 for the three
months ended September 30, 2005.

     The following table shows the breakdown by business segment for the three
months ended September 30:

Business Segment                      2006            2005    % Increase
                                      ----            ----    (decrease)
                                                              ----------
Pharmacies                       $ 3,141,499     $ 2,569,365     22.3
Medical                              422,733         521,054    (18.9)
Corporate                            162,277          97,666     66.2
                                 -----------     -----------
                                 $ 3,726,509     $ 3,188,085     16.9
                                 ===========     ===========
     The pharmacies' S,G&A expenses increased $572,134 to $3,141,499 or 22.3%
for the three months ended September 30, 2006 as compared to $2,569,365 for the
three months ended September 30, 2005, mainly due to increased labor costs of
approximately $341,000.  The increased labor costs consisted of approximately
$212,000 due to the short supply of pharmacists and pharmacy technicians and
additional personnel due to increased revenues and approximately $128,300 of
the increase was due to a pharmacy opened in April 2006.  The balance of the
increase was composed of advertising expense of $69,035, equipment rental of
$35,410, LIFO expense of $35,000, rent expense of $24,450, legal expense of
$22,250, depreciation and amortization expense of $23,135, and insurance
expense  of $10,220.  The remaining increase of $11,634 was a combination of
miscellaneous operating expenses.

     The medical segment's S,G&A expenses decreased $98,321 or 18.9% to
$422,733 for the three months ended September 30, 2006 as compared to $521,054
for the three months ended September 30, 2005.  The decrease was due to the
following: a decrease in the allowance for bad debt expense of $40,000, a
reduction in sales related expenses of $32,700, decrease in shipping charges of
$16,500 and reduced bulk inventory storage costs and expenses of $9,500.
                                          16

FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                      NYER MEDICAL GROUP, INC. AND SUBSIDIARIES

Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
         RESULTS OF OPERATIONS, continued,

Results of Operations: continued,

Selling, General and Administrative Expenses: continued,

     The Corporate segment's overhead increased by $64,611 or 66.2% to $162,277
for the three months ended September 30, 2006 as compared to $97,666 for the
three months ended September 30, 2005 due to increased legal fees of
approximately $44,000, fees paid to the minority shareholders for an extension
of $33,330 (for additional information see Note 3,) and increased board and
audit committee expenses of $13,820.  These increases were partially offset by
a reduction in personnel costs of approximately  $21,500.

Interest Expense:  Interest expense increased by $4,227 or 168.4% for the three
months ended September 30, 2006 to $6,737 as compared to $2,510 for the three
months ended September 30, 2005.

    The following table shows the breakdown of interest expense by business
segment for the three months ended September 30:

Business Segment                 2006            2005     %Increase (decrease)
                                 ----            ----     -------------------
Pharmacies                  $     6,638     $     2,134        211.1
Medical                              99             376        (73.7)
                            ===========     ===========
                            $     6,737     $     2,510        168.4
                            ===========     ===========
     The pharmacies' interest expense increased $4,504 or 211.1% to 6,638 for
the three months ended September 30, 2006 as compared to $2,134 for the three
months ended September 30, 2005 due to interest on a note for the acquisition
of a pharmacy in April 2006.

     The medical segment's interest expense decreased $277 or 73.7% to $99 for
the three months ended September 30, 2006 as compared to $376 for the three
months ended September 30, 2005.

Minority Interest.  Minority interest for the pharmacy segment decreased by
$10,940 or 34.1% to $21,159 for the three months ended September 30, 2006 as
compared to $32,099 for the three months ended September 30, 2005.  The
decrease was due to lower net income in the pharmacy segment.

Income Tax Expense.  Income tax expense decreased by $61,500 or 67.3% to
$29,900 for the three months ended September 30, 2006 as compared to $91,400
for the three months ended September 30, 2005.  The income tax expense
decreased due to less net income.  The Company's income tax expenses are higher
than expected due to the pharmacy segment's state tax accrual in Massachusetts
and the other subsidiaries losses in other states were not available to offset
the tax.

    The following table shows the breakdown of income tax expense by business
segment for the three months ended September 30:

Business Segment                      2006            2005    %(decrease)
                                      ----            ----    ----------
Pharmacies                       $    75,300     $   107,000     (29.6)
Medical                                 (400)          6,500    (106.2)
Corporate                            (45,000)        (22,100)   (103.6)
                                 -----------     -----------
                                 $    29,900     $    91,400     (67.3)
                                ============     ===========
                                          17



FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                      NYER MEDICAL GROUP, INC. AND SUBSIDIARIES

Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
         RESULTS OF OPERATIONS, continued,

Results of Operations: continued,

Liquidity and Capital Resources

     Net cash provided by operating activities was $471,503 for the three
months ended September 30, 2006 as compared to net cash flows used in operating
activities of $653,522 for the three months ended September 30, 2005.  The
primary uses of cash were to fund operations.

     Net cash used in investing activities was $46,602 for the three months
ended September 30, 2006 as compared $80,749 for the three months ended
September 30, 2005.  The cash used was to purchase property, plant and
equipment.

     Net cash used in financing activities was $47,648 for three months ended
September 30, 2006 as compared to $42,512 for the three months ended September
30, 2005.  The cash used was for repayments of long-term debt.

     At September 30, 2006, cash on a consolidated basis was $1,191,372 as
compared to $814,119 at June 30, 2006.  The approximate cash balances of the
Company and subsidiaries were as follows:  pharmacies - $1,101,000, medical -
$82,000 and the Company - $8,100.  Because the pharmacies are not a
wholly-owned subsidiary of the Company and the Company does not have operating
control, it cannot unilaterally cause the pharmacies to loan funds to the
Company should the Company require a loan.  The pharmacies owe approximately
$22,000 to the Company which is being repaid monthly.  The pharmacies increase
was principally due to a reduction in accounts receivable of approximately
$400,000.

     The medical and corporate segments obtained a $300,000 line of credit
which expires November 30, 2006.  The Company intends to renew the line of
credit.  The line of credit is collateralized by property owned by the
subsidiary and is guaranteed by the Company.  As of the date of this report,
the Company has not drawn on the line of credit.

     At September 30, 2006, we had net accounts receivable of $4,830,902
as compared to $5,244,779 at June 30, 2006.  Accounts receivable decreased due
to increased collections from the pharmacy segment and the medical segment's
decrease in sales and reduction in allowance for doubtful accounts.

     At September 30, 2006, debt was $434,819 as compared to $482,467 at June
30, 2006.  Our debt has decreased due to pay down on existing debt.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

     We do not have any material risk with respect to changes in interest
rates, foreign currency exchange rates, commodities prices or other relevant
market rates or prices over a selected period of time.

     Please note that we do not have any interest bearing investments and our
debt is not subject to market risk and fluctuations because all of the debt
has fixed maturity dates and fixed interest rates.  The difference between the
Company's carrying amount and fair value of its long-term debt was immaterial
at September 30, 2006.


                                          18

   FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                      NYER MEDICAL GROUP, INC. AND SUBSIDIARIES

Item 4.  Controls and Procedures

     The Company's management evaluated, with the participation of its principal
executive officer and principal financial officer, the effectiveness of its
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)
under the Securities Exchange Act of 1934) as of the end of the period covered
by this report.  Based on such evaluation, the principal executive officer
and principal financial officer of the Company concluded that its disclosure
controls and procedures are designed to ensure that information required to be
disclosed by the Company in the reports that it files or submits under the
Securities Exchange Act of 1934 is recorded, processed, summarized and reported
within the time periods specified in the rules and regulations of the
Securities and Exchange Commission and is operating in an effective manner.

     No change in the Company's internal control over financial reporting (as
defined in Rules 13a-15(f) and 15(d)-15(f) under the Securities Exchange Act of
1934) occurred during the most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, its internal control
over financial reporting.

                            PART II - Other Information

Item 1.  Legal Proceedings

    The Company is subject to various legal proceedings and threatened legal
proceedings from time to time as part of its business.

     In April, 2006, a former employee of the pharmacy segment filed a civil
action against the pharmacy segment in the United States District Court for the
District of Massachusetts, alleging that the pharmacy segment improperly
classified its pharmacists as exempt from the overtime requirements of the Fair
Labor Standards Act and failed to make overtime payments to them under the FLSA
and an analogous state law.  The former employee sought payment of overtime from
April 2003 through April 2006, penalties and attorney's fees.  The action
originally was brought as a class action.  At a status conference before the
court on September 25, 2006, the plaintiffs' counsel stated that the former
employee would not seek certification of a class and, therefore, that the claim
would proceed solely on behalf of the former employee.  Based on this
representation, the Company concluded that the claim was not material.  On
October 20, 2006, the pharmacy segment and the former employee settled this
matter with the pharmacy segment agreeing to pay the former employee the total
amount of $15,000.

     In April, 2006, the former employee also filed a Charge of Discrimination
with the Massachusetts Commission Against Discrimination ("MCAD") against the
pharmacy segment and an officer of the pharmacy segment, alleging that the
former employee was subjected to discrimination and sexual harassment that
resulted in her constructive termination.  The pharmacy segment filed a
position statement with the MCAD on June 26, 2006 denying the allegations and
requesting that the MCAD issue a lack of probable cause finding and dismiss the
charge. On August 16, 2006, the former employee withdrew the Charge of
Discrimination from the MCAD, and, the next day, filed a civil action in the
Middlesex Division of the Superior Court Department of the Massachusetts Trial
Court raising allegations identical to those in the MCAD charge.  The complaint
seeks back pay, emotional distress and punitive damages and attorneys' fees in
unspecified amounts.  The pharmacy segment filed its answer on September 14,
                                          19

FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                       NYER MEDICAL GROUP, INC. AND SUBSIDIARIES

                            PART II - Other Information, continued

Item 1.  Legal Proceedings, continued

2006, and discovery has commenced.  The likelihood of success of this
litigation matter has not yet been determined.  Accordingly the Company cannot
determine at this time if the claim is material.

     Anton Investments, Inc. and Conway Associates, Inc. have litigation
threatened against them with respect to amounts owed.  The entities have not
yet determined the likelihood of success of these potential litigation matters.
The Company does not believe that the dollar amount of possible damages
regarding these litigation matters threatened would be material.  Even if these
matters were all decided in a manner adverse to the Company, there would not
likely be a material adverse affect on the Company and its subsidiaries.  It
should be noted that this paragraph describes litigation which has been
threatened but for which no complaint has been filed against the Company or any
of its subsidiaries.  It is possible that no suit will be filed with respect to
these matters.

     Any potential litigation, regardless of its merits, could result in costs
to the Company and divert management's attention from operations.

Item 1A.  Risk Factors

     The Risk Factors included in the Company's Annual Report on Form 10-
K/Amendment No. 1 for the fiscal year ended June 30, 2006 have not materially
changed.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

      The foregoing equity repurchases by the Company during the fiscal quarter
ended September 30, 2006 have been reflected as follows:

                        ISSUER PURCHASES OF EQUITY SHARES
                                                           (d)Maximum Number
                                                            (or) Approximate
                                        c) Total Number of   Dollar Value)of
                                        Shares Purchased as  Shares that May
                                          Part of Publicly   Yet Be Purchased
    (a)Total Number of (b)Average Price  Announced Plans or  Under the Plans or
   Shares Purchased   Paid Per Share    Programs             Programs

July 1 - 31       0               $ -                0                 148,000
August 1 - 31     0               $ -                0                 148,000
September 1 - 30  0               $ -                0                 148,000

     On May 12, 2003, the Company announced that the Board of Directors of the
Company had authorized the repurchase of up to 150,000 shares of the Company's
outstanding common stock from time-to-time in open market transactions at
prevailing market prices.  There was no expiration date established for this
repurchase plan.  As of the date of this report, the plan has not been
terminated.




                                          20


FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                       NYER MEDICAL GROUP, INC. AND SUBSIDIARIES


Item 3.  Defaults Upon Senior Securities                          None

Item 4.  Submissions of Matters to a Vote of Security Holders     None

Item 5.  Other Information                                        None

Item 6.  Exhibits

      Exhibit 10.1  Agreement, dated as of August 9, 2006, by and among
        Nyer Medical Group, Inc., Mark A. Dumouchel, David Dumouchel, Lucille
        Curry, Michael Curry, Donato Mazzola, Wayne Gunter, D.A.W., Inc. and
        F.M.T. Franchise Co., Inc. (incorporated by reference to Exhibit 99.1
        to the registrant's Current Report on Form 8-K filed on August 9,
        2006 with the Securities and Exchange Commission).

   Exhibit 10.2  Pledge Agreement, dated as of August 14, 2006, by Nyer
     Medical Group, Inc. in favor of D.A.W., Inc. (incorporated by reference
     to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on
     August 16, 2006 with the Securities and Exchange Commission).

   Exhibit 10.3  five separate employment agreements, each dated August 5,
2006, by each of Michael Curry, David Dumouchel, Mark Dumouchel, Wayne Gunter
and Donato Mazzola, separately, with D.A.W., Inc. (oral and not written)
(incorporated by reference to the registrant's Current Report on Form
8-K filed on September 27, 2006 with the Securities and Exchange Commission).

   Exhibit 10.4  Amendment to Employment Agreement, dated as of July 1, 2006,
between Nyer Medical Group, Inc. and Karen Wright (oral and not written)
(incorporated by reference to the registrant's Current Report on Form
8-K filed on September 27, 2006 with the Securities and Exchange Commission).

   Exhibit 10.5  Supply Agreement, dated July 1, 2006, between McKesson
Corporation and D.A.W., Inc. (incorporated by reference to Exhibit 10.1 to the
registrant's Current Report on Form 8-K filed on November 14, 2006 with the
Securities and Exchange Commission). (Portions of this exhibit have been
omitted pursuant to a request for confidential treatment.)

   Exhibit 31.1  Certification Pursuant to Rules 13a-14(a) and 15d-14(a)
of the Securities Exchange Act of 1934 and Section 302 of the Sarbanes-Oxley
Act of 2002 by Principal Executive Officer and Principal Financial and
Accounting Officer.

   Exhibit 32.1  Certification Pursuant to 18 U.S.C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by President,
Chief Executive Officer and Chief Financial Officer.











                                          21


FORM 10-Q        NYER MEDICAL GROUP, INC.  000-20175       SEPTEMBER 30, 2006
                       NYER MEDICAL GROUP, INC. AND SUBSIDIARIES

                                    SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.




                                     NYER MEDICAL GROUP, INC.
                                     Registrant



  Date:  November 14, 2006           By:/s/ Karen L. Wright

                                     Karen L. Wright, President,
                                     Principal Executive Officer,
                                     Chief Executive Officer,
                                     Principal Financial and Accounting
                                     Officer and Chief Financial
                                     Officer








                                          22
EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Karen L. Wright, certify that:

   1.  I have reviewed this quarterly report on Form 10-Q of Nyer Medical
        Group, Inc.;

   2.  Based on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;

   3.  Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;

   4.  The registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

   (a) Designed such disclosure controls and procedures, or caused such
      disclosure controls and procedures to be designed under our supervision,
      to ensure that material information relating to the registrant,
      including its consolidated subsidiaries, is made known to us by others
      within those entities, particularly during the period in which this
      report is being prepared;
   (b) Evaluated the effectiveness of the registrant's disclosure controls and
      procedures and presented in this report our conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end
      of the period covered by this report based on such evaluation; and

   (c) Disclosed in this report any change in the registrant's internal control
      over financial reporting that occurred during the registrant's most
      recent fiscal quarter (the registrant's fourth fiscal quarter in the
      case of an annual report) that has materially affected, or is reasonably
      likely to materially affect, the registrant's internal control over
      financial reporting; and

   5.  The registrant's other certifying officer(s) and I have disclosed, based
on our most recent evaluation of internal control over financial reporting, to
the registrant's auditors and the audit committee of the registrant's board
       of directors (or persons performing the equivalent functions):

   (a) All significant deficiencies and material weaknesses in the design or
      operation of internal control over financial reporting which are
      reasonably likely to adversely affect the registrant's ability to
      record, process, summarize and report financial information; and

   (b) Any fraud, whether or not material, that involves management or other
      employees who have a significant role in the registrant's internal
      control over financial reporting.

Date:  November 14, 2006

 /s/ Karen L. Wright
     Karen L. Wright
     President
     (Principal Executive Officer)
     Vice President - Finance
     (Principal Financial and Accounting Officer)


                                          23
Exhibit 32.1

CERTIFICATION PURSUANT TO   18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the Quarterly Report of Nyer Medical Group, Inc. (the
"Company") on Form 10-Q for the quarter ended September 30, 2006, as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Karen L. Wright, President, Chief Executive Officer and Chief Financial Officer
of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of
my knowledge:

(1)  The Report fully complies with the requirements of section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and

(2)  The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.


Date:  November 14, 2006


/s/ Karen L. Wright
    Karen L. Wright,
    President, Chief Executive Officer
    and Chief Financial Officer
















                                          24